ArticleFrontiers in pharmacology2026
Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative depression is a common complication following non-small cell lung cancer (NSCLC) resection, which adversely affects quality of life and may impede long-term survival. Modified Sini Powder (MSNP), a modified traditional Chinese medicine formula derived from classical Sini Powder, has been used in clinical practice to alleviate depressive symptoms. However, comprehensive evidence from well-designed clinical trials remains insufficient. This protocol describes a study designed to evaluate the efficacy and safety of MSNP in managing postoperative mild-to-moderate depression in patients with NSCLC and to characterize its biological mechanisms. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 468 postoperative patients with NSCLC and mild-to-moderate depression will be recruited across nine tertiary medical centers. Participants will be stratified by concomitant paroxetine use and randomized in a 1:1 ratio within each stratum to receive an MSNP-containing intervention or the corresponding placebo control for 6 weeks. The primary outcome is the total effective rate at the end of treatment, defined as a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score from baseline. Secondary outcomes include measures of anxiety, sleep quality, fear of cancer recurrence, quality of life, and survival. Safety will be monitored through adverse event reporting and laboratory examinations. Mechanistic explorations will integrate analyses of inflammatory cytokines, hypothalamic-pituitary-adrenal axis hormones, neurotransmitters, brain-derived neurotrophic factor, serum metabolomics, and gut microbiota profiles. Discussion: This trial aims to provide robust clinical evidence for the integration of MSNP into the management of postoperative mild-to-moderate depression in patients with NSCLC. Furthermore, multi-omics analyses are expected to elucidate the multi-target and multi-pathway mechanisms of MSNP, offering insights into personalized and integrative therapeutic strategies. Trial Registration: Registered on September 1, 2025, at the International Traditional Medicine Clinical Trial Registration Center (https://itmctr.ccebtcm.org.cn/mgt/project/view/1962361959055753216; Identifier: ITMCTR2025001642).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.